Arcus biosciences, inc. (RCUS)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Collaboration and license revenue

0

-

-

-

0

-

-

-

-

-

-

-

-

Collaboration and license revenue

-

-

6,812

9,353

-

8,353

0

0

0

-

0

-

-

Operating expenses:
Research and development

86,069

78,481

69,230

64,848

53,548

49,646

50,355

58,931

53,066

47,218

0

0

0

General and administrative

27,267

25,228

22,248

18,067

15,606

13,566

12,404

10,689

9,069

7,636

0

0

0

Total operating expenses

113,336

103,709

91,478

82,915

69,154

63,212

62,759

69,620

62,135

54,854

0

0

0

Loss from operations

-98,336

-88,709

-84,666

-73,562

-60,301

-54,859

-54,718

-65,707

-59,472

-53,441

0

0

0

Non-operating income (expense):
Non-operating income (expense):
Interest and other income, net

4,314

5,201

5,782

6,047

5,853

4,922

0

0

0

-

-

-

-

Gain on deemed sale from equity method investee

482

0

0

1,229

0

-

0

0

-

-

-

-

-

Share of loss from equity method investee

-1,253

-1,202

-1,523

-1,352

-1,091

-886

0

0

0

-

-

-

-

Total non-operating income, net

3,543

3,999

4,259

4,695

5,991

5,265

4,209

2,888

636

359

0

0

0

Net loss

-94,793

-84,710

-80,407

-68,867

-54,310

-49,594

-50,509

-62,819

-58,836

-53,082

0

0

0

Other comprehensive income

259

171

162

196

126

-65

-99

-60

-63

-16

0

0

0

Comprehensive loss

-94,534

-84,539

-80,245

-68,671

-54,184

-49,659

-50,608

-62,879

-58,899

-53,098

0

0

0

Net loss per share, basic and diluted

-0.63

-0.37

-0.51

-0.64

-0.41

0.51

-0.25

-0.32

-1.37

-6.57

-11.86

-5.64

-4.96

Weighted-average number of shares used to compute basic and diluted net loss per share

44,282

44,058

43,939

43,797

43,508

43,612

42,838

42,533

9,488

2,218

1,949

1,693

1,452